trial · primary record
68Ga-DOTA-TATE PET Scan
Thyroid Cancer
| Phase | Phase 1, Phase 2 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 18 |
| Primary completion | 2032-08-01 |
| Primary endpoint | To determine the optimal dose of 177Lu-DOTA-EB-TATE that is both safe and shows sufficient efficacy for treatment of metastatic HTC based on TITE-BOIN12 design of phase 1/2 clinical trial [1, 2]. |
| Registry ID | NCT06991738 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-28T02:32:46.089Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT06991738
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.